Clinical trial
Comparison of Intravenously Administered Dexmedetomidine Versus Clonidine Versus No Alpha-2 Agonist on Emergence Delirium, PACU Length of Stay, and Time to Hospital Discharge in Children Undergoing (Adeno)Tonsillectomy: A Prospective Observational Study
NCT07913308 is registered in ClinicalTrials.gov with Universitair Ziekenhuis Brussel as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing
Registry record
As filed in ClinicalTrials.gov.
- Title
- Comparison of Intravenously Administered Dexmedetomidine Versus Clonidine Versus No Alpha-2 Agonist on Emergence Delirium, PACU Length of Stay, and Time to Hospital Discharge in Children Undergoing (Adeno)Tonsillectomy: A Prospective Observational Study
- Lead sponsor
- Universitair Ziekenhuis Brussel
- Phase
- Observational
- Overall status
- Not yet recruiting
- Start date
- December 1, 2026
- Completion date
- May 31, 2027
- Enrollment
- 150 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
adenotonsillectomy, emergency delirium, length of stay, pediatric anesthesia complications, post anesthesia care unit length of stay, postoperative delirium (pod), postoperative pain, tonsillectomy
Arms
As registered; 3 arms.
-
Dexmedetomidine Group
Pediatric patients undergoing elective (adeno)tonsillectomy with or without placement of myringotomy tubes who receive intraoperative intravenous dexmedetomidine as part of standard anesthetic care, at the discretion of the attending anesthesiologist.
-
Clonidine Group
Pediatric patients undergoing elective (adeno)tonsillectomy with or without placement of myringotomy tubes who receive intraoperative intravenous clonidine as part of standard anesthetic care, at the discretion of the attending anesthesiologist.
-
Control Group (No Alpha-2 Agonist)
Pediatric patients undergoing elective (adeno)tonsillectomy with or without placement of myringotomy tubes who do not receive any intraoperative alpha-2 adrenergic agonist (dexmedetomidine or clonidine) as part of standard anesthetic care.
Primary endpoints
Registered primary outcome measures; 1 primary.
-
Incidence and Severity of Emergence Delirium (ED)
Emergence delirium will be assessed using the Pediatric Anesthesia Emergence Delirium (PAED) scale. The PAED scale consists of 5 items, with total scores ranging from 0 to 20, where higher scores indicate greater severity of delirium. A PAED score \>= 10 (or \>= 12) is defined as the presence of emergence delirium.
Patents and exclusivity
By drug, as the FDA Orange Book declares its patents.
-
CLONIDINE
- US 12551466; expires August 22, 2045; assignee not stated
- US 12233049; expires July 15, 2042; assignee Slayback Pharma LLC
- US 12440474; expires July 15, 2042; assignee Azurity Pharmaceuticals
- US 12721837; expires July 15, 2042; assignee not stated
- US 11918689; expires July 28, 2041; assignee Tris Pharma (United States)
- +4 more patents
-
DEXMEDETOMIDINE
- US 11806334; expires January 12, 2043; assignee BioXcel Therapeutics, Inc.
- US 11998528; expires January 12, 2043; assignee BioXcel Therapeutics, Inc.
- US 12090140; expires January 12, 2043; assignee BioXcel Therapeutics, Inc.
- US 12138247; expires January 12, 2043; assignee BioXcel Therapeutics, Inc.
- US 12364683; expires January 12, 2043; assignee BioXcel Therapeutics, Inc.
- +18 more patents
Lead sponsor's other trials
Universitair Ziekenhuis Brussel, most recent start first.
+387 more trials See the organization page
Similar trials
Same condition (Emergence Delirium) and phase, most recent start first.
+271 more trials See the condition page